Generic drug industry leaders are lining up behind a proposal to pay user fees to the government as a way to speed approval of drugs and plant inspections, say several industry chiefs.
The heads of Mylan Inc. and Watson Pharmaceuticals Inc. said they are trying to break backlogs at the Food and Drug Administration, where copycat medicines now take an average of 2½ years to get approval.
At the annual gathering of the Generic Pharmaceutical Association this week in Orlando, Fla., industry chiefs hope to hammer out a unified plan in advance of negotiations over user fees that begin on ...
No comments:
Post a Comment